Impact of Osmotically Active Excipients on Bioavailabil III Drugs

AAPS Journal 15, 1043-1050 DOI: 10.1208/s12248-013-9509-z

Citation Report

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Biowaiver and Biopharmaceutics Classification System. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 119-137. | 0.2 | 2 |
| 2 | Novel insights into excipient effects on the biopharmaceutics of APIs from different BCS classes: Lactose in solid oral dosage forms. European Journal of Pharmaceutical Sciences, 2014, 61, 27-31. | 1.9 | 16 |
| 3 | Drug–Drug Interactions Related to Altered Absorption and Plasma Protein Binding: Theoretical and Regulatory Considerations, and an Industry Perspective. Journal of Pharmaceutical Sciences, 2015, 104, 916-929. | 1.6 | 21 |
| 4 | Comprehensive quantitative analysis of Chinese patent drug YinHuang drop pill by ultra high-performance liquid chromatography quadrupole time of flight mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 125, 415-426. | 1.4 | 10 |
| 5 | Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses. AAPS Journal, 2016, 18, 1500-1511. | 2.2 | 24 |
| 6 | Considerations and recommendations on traditional and non-traditional uses of excipients in oral drug products. AAPS Open, 2016, 2, . | 0.4 | 8 |
| 7 | Polymersomes via Self-Assembly of Amphiphilic β-Cyclodextrin-Centered Triarm Star Polymers for Enhanced Oral Bioavailability of Water-Soluble Chemotherapeutics. Biomacromolecules, 2016, 17, 1026-1039. | 2.6 | 32 |
| 8 | Reflection on the Pharmaceutical Formulation Challenges Associated with a Paediatric Investigation Plan for an Off-Patent Drug. AAPS PharmSciTech, 2017, 18, 250-256. | 1.5 | 14 |
| 9 | Product and Process Development of Solid Oral Dosage Forms. , 2017, , 555-591. | | 8 |
| 10 | Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. International Journal of Pharmaceutics, 2017, 519, 79-97. | 2.6 | 81 |
| 11 | In Vitro and In Vivo Inhibition of Intestinal Glucose Transport by Guava (<i>Psidium Guajava</i>) Extracts. Molecular Nutrition and Food Research, 2018, 62, e1701012. | 1.5 | 27 |
| 12 | Patient acceptability, safety and access: A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations. International Journal of Pharmaceutics, 2018, 536, 547-562. | 2.6 | 69 |
| 13 | Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open‣abel, Randomized Study. Clinical Pharmacology and Therapeutics, 2018, 103, 402-408. | 2.3 | 25 |
| 14 | Effects of Sorbitol on the Pharmacokinetics of Lamivudine Solution and the FDA's Decision to Increase the Dose of Lamivudine Solution for Pediatric Patients. Clinical Pharmacology and Therapeutics, 2018, 104, 785-787. | 2.3 | 2 |
| 15 | Intestinal absorption-modifying excipients: A current update on preclinical in vivo evaluations. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 411-420. | 2.0 | 28 |
| 16 | Author's Reply to Trechot: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?â€: Clinical Pharmacokinetics, 2019, 58, 979-980. | 1.6 | Ο |
| 17 | Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?― Clinical Pharmacokinetics, 2019, 58, 973-975. | 1.6 | 2 |
| 18 | Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?. Clinical Pharmacokinetics, 2019, 58, 827-833. | 1.6 | 34 |

CITATION REPORT

| # | Article | IF | CITATIONS |
|----|---|------------------|-----------------------------|
| 19 | Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse. Journal of Clinical Pharmacology, 2019, 59, 625-637. | 1.0 | 10 |
| 20 | Effect of excipients on oral absorption process according to the different gastrointestinal segments. Expert Opinion on Drug Delivery, 2021, 18, 1005-1024. | 2.4 | 8 |
| 21 | Transverse comparison of mannitol content in marketed drug products: Implication for no-effect dose of sugar alcohols on oral drug absorption. Journal of Drug Delivery Science and Technology, 2020, 57, 101728. | 1.4 | 6 |
| 22 | Preparation, Optimization, and Evaluation of Methoxy Poly(ethylene) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Chemical Neuroscience, 2020, 11, 783-795. | 50 627 To 1.7 | l (glycol)- <i>0 25</i> |
| 23 | The Provisional No-Effect Threshold of Sugar Alcohols on Oral Drug Absorption Estimated by Physiologically Based Biopharmaceutics Model. Journal of Pharmaceutical Sciences, 2021, 110, 467-477. | 1.6 | 11 |
| 24 | Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of <i>In Vivo</i> Clinical Studies: Current Status, Challenges, and Opportunities. Molecular Pharmaceutics, 2021, 18, 1-17. | 2.3 | 9 |
| 25 | Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride. Journal of Pharmaceutical Sciences, 2021, 110, 1513-1526. | 1.6 | 8 |
| 26 | Digoxin absorption decreased independently of P-gp activity in rats with irinotecan-induced gastrointestinal damage. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 24. | 0.4 | 1 |
| 27 | Improved Hygroscopicity and Bioavailability of Solid Dispersion of Red Ginseng Extract with Silicon Dioxide. Pharmaceutics, 2021, 13, 1022. | 2.0 | 13 |
| 28 | Assessing CYP2C8-Mediated Pharmaceutical Excipient-Drug Interaction Potential: A Case Study of Tween 80 and Cremophor ELâ~'35. Pharmaceutics, 2021, 13, 1492. | 2.0 | 3 |
| 29 | Potential pharmacokinetic interaction between orally administered drug and osmotically active excipients in pediatric polypharmacy. European Journal of Pharmaceutical Sciences, 2021, 165, 105934. | 1.9 | 2 |
| 30 | Osmotic-controlled release oral tablets: technology and functional insights. Trends in Biotechnology, 2022, 40, 606-619. | 4.9 | 10 |
| 31 | Evaluation of Excipient Risk in BCS Class I and III Biowaivers. AAPS Journal, 2022, 24, 20. | 2.2 | 16 |
| 32 | Tailoring functional nanoparticles for oral vaccine delivery: Recent advances and future perspectives. Composites Part B: Engineering, 2022, 236, 109826. | 5.9 | 22 |
| 33 | Progress in Quantitative Methods for Azelnidipine and Chlorthalidone: An Analytical Basis for a Recently Approved FDC. Current Pharmaceutical Analysis, 2023, 19, 66-82. | 0.3 | 1 |
| 34 | Approaches of formulation bridging in support of orally administered drug product development. International Journal of Pharmaceutics, 2022, , 122380. | 2.6 | 0 |
| 35 | The Rat Continuous Intestine Model Predicts the Impact of Particle Size and Transporters on the Oral Absorption of Glyburide. Molecular Pharmaceutics, 0, , . | 2.3 | 0 |
| 36 | Polyols Permeability on Caco-2 Cells and Their Effects on Transport of Low-Permeability Drugs. Future Pharmacology, 2023, 3, 229-237. | 0.6 | ο |

| # | Article | IF | CITATIONS |
|----|---|----|-----------|
| 40 | Preformulation considerations in pharmaceutical formulation process. , 2024, , 395-441. | | 0 |